• Episode 16: ESMO 2024 Commentary: Kidney Cancer

  • Sep 26 2024
  • Length: 22 mins
  • Podcast

Episode 16: ESMO 2024 Commentary: Kidney Cancer

Listen for free

View show details

  • Summary

  • Wrapping up their ESMO Congress 2024 coverage with a discussion of renal cancer, our hosts talk about what strategies work (or don’t) after frontline therapy for mRCC, implications on adjuvant therapy, as well as major efforts for non-clear cell histologies like the SUNNIFORECAST trial.

    The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca


    This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, J&J Innovative Medicine, Merck, Novartis, Pfizer, TerSera.
    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2
Show more Show less

What listeners say about Episode 16: ESMO 2024 Commentary: Kidney Cancer

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available